Phathom Pharmaceuticals, Inc. (PHAT) Q4 FY25 Earnings Call

GI execution supports 2026 growth and Q3 profitability, but seasonality, margin pressure, and Medicare access limit near-term visibility.

Q4 FY25 results, source: company transcript and SEC filings
QuarterQ4 FY25
Call date2026-03-02
Length52 minutes
EPS$-0.16
EPS consensus$-0.20
Revenue$49.5M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q2 FY26

All PHAT earnings ยท Back to PHAT overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.